The CTGF gene -945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Patel, Sheila K ^a   Wai, Bryan ^a,b   MacIsaac, Richard J ^c   Grant, Sharon ^a   Velkoska, Elena ^a   Ord, Michelle ^b   Panagiotopoulos, Sianna ^b   Jerums, George ^a,b   Srivastava, Piyush M ^a,b   Burrell, Louise M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cardiac fibrosis; Chronic kidney disease.; Connective tissue growth factor; CTGF; Type 2 diabetes

Indexed keywords

ALBUMIN; CONNECTIVE TISSUE GROWTH FACTOR;

ADULT; ALBUMINURIA; ARTICLE; BODY MASS; CAUCASIAN; CHRONIC KIDNEY DISEASE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; URINARY EXCRETION;

AGED; ALBUMINURIA; CHI-SQUARE DISTRIBUTION; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIASTOLE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VICTORIA;

EID: 84860183620     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-42     Document Type: Article

References (45)

1. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008, 4:575-596. 2515418, 18827908.
2. Leask A. Getting to the heart of the matter: CCN2 plays a role in cardiomyocyte hypertrophy. J Cell Commun Signal 2010, 4:73-74. 10.1007/s12079-009-0061-7, 2821479,2821479, 19701807.
3. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf) 2009, 195:321-338.
4. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000, 32:1805-1819. 10.1006/jmcc.2000.1215, 11013125.
5. Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, Azuma J. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 2008, 370:274-278. 10.1016/j.bbrc.2008.03.100, 18375200.
6. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993, 4:637-645. 300970, 8374172.
7. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM, Burrell LM. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 2005, 53:1245-1256. 10.1369/jhc.4A6560.2005, 15956033.
8. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003, 92:785-792. 10.1161/01.RES.0000065620.39919.20, 12623881.
9. Au CG, Butler TL, Sherwood MC, Egan JR, North KN, Winlaw DS. Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol 2011, 92:57-65. 10.1111/j.1365-2613.2010.00750.x, 3052757, 21121985.
10. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002, 51:2709-2718. 10.2337/diabetes.51.9.2709, 12196463.
11. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991, 68:85-89. 10.1016/0002-9149(91)90716-X, 2058564.
12. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002, 359:1430-1432. 10.1016/S0140-6736(02)08358-7, 11978359.
13. Srivastava PM, Calafiore P, Macisaac RJ, Patel SK, Thomas MC, Jerums G, Burrell LM. Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. Clin Sci (Lond) 2008, 114:313-320.
14. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. Kidney Int 1999, 56:1627-1637. 10.1046/j.1523-1755.1999.00721.x, 10571771.
15. Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, Mason RM. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001, 359:77-87. 10.1042/0264-6021:3590077, 1222123, 11563971.
16. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998, 53:853-861. 10.1111/j.1523-1755.1998.00820.x, 9551391.
17. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000, 11:25-38.
18. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, Schlingemann RO, Goldschmeding R. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004, 27:1164-1170. 10.2337/diacare.27.5.1164, 15111539.
19. Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, van Nieuwenhoven FA, Goldschmeding R. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 2008, 31:1177-1182. 10.2337/dc07-2469, 18344285.
20. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, Langham RG, Jerums G. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 2003, 26:2632-2636. 10.2337/diacare.26.9.2632, 12941731.
21. Blom IE, van Dijk AJ, de Weger RA, Tilanus MG, Goldschmeding R. Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms. Mol Pathol 2001, 54:192-196. 10.1136/mp.54.3.192, 1187061, 11376134.
22. Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, Spagnolo P, Pantelidis P, Leoni P, McHugh N, Stock CJ, Shi-Wen X, Denton CP, Black CM, Welsh KI, du Bois RM, Abraham DJ. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007, 357:1210-1220. 10.1056/NEJMoa067655, 17881752.
23. Patel SK, Wai B, Ord M, Macisaac RJ, Grant S, Velkoska E, Panagiotopoulos S, Jerums G, Srivastava PM, Burrell LM. Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in caucasians with type 2 diabetes. Am J Hypertens 2012, 25:216-222. 10.1038/ajh.2011.188, 21993363.
24. American Diabetes Association Standards of medical care in diabetes--2012. Diabetes Care 2012, 35(Suppl 1):S11-S63. American Diabetes Association.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
26. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012, 379:165-180. 10.1016/S0140-6736(11)60178-5, 21840587.
27. Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, Wilson PW. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006, 114:1083-1087. 10.1161/CIRCULATIONAHA.106.177321, 16894032.
28. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
29. Srivastava PM, Thomas MC, Calafiore P, MacIsaac RJ, Jerums G, Burrell LM. Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clin Sci (Lond) 2006, 110:109-116.
30. International HapMap Consortium The International HapMap Project. Nature 2003, 426:789-796. 10.1038/nature02168, 14685227, International HapMap Consortium.
31. Meune C, Vignaux O, Kahan A, Allanore Y. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010, 103:46-52. 10.1016/j.acvd.2009.06.009, 20142120.
32. Gourh P, Mayes MD, Arnett FC. CTGF polymorphism associated with systemic sclerosis. N Engl J Med 2008, 358:308-309.
33. Louthrenoo W, Kasitanon N, Wichainun R, Wangkaew S, Sukitawut W, Ohnogi Y, Kuwata S, Takeuchi F. Lack of CTGF*-945C/G Dimorphism in Thai Patients with Systemic Sclerosis. Open Rheumatol J 2011, 5:59-63. 10.2174/1874312901105010059, 3204428, 22046208.
34. Rueda B, Simeon C, Hesselstrand R, Herrick A, Worthington J, Ortego-Centeno N, Riemekasten G, Fonollosa V, Vonk MC, van den Hoogen FH, Sanchez-Roman J, Aguirre-Zamorano MA, Garcia-Portales R, Pros A, Camps MT, Gonzalez-Gay MA, Gonzalez-Escribano MF, Coenen MJ, Lambert N, Nelson JL, Radstake TR, Martin J. A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann Rheum Dis 2009, 68:1618-1620. 10.1136/ard.2008.100180, 2743760, 19054816.
35. Tu E, Bagnall RD, Duflou J, Lynch M, Twigg SM, Semsarian C. Post-mortem pathologic and genetic studies in "dead in bed syndrome" cases in type 1 diabetes mellitus. Hum Pathol 2010, 41:392-400. 10.1016/j.humpath.2009.08.020, 20004937.
36. Dendooven A, Nguyen TQ, Brosens L, Li D, Tarnow L, Parving HH, Rossing P, Goldschmeding R. The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. J Negat Results Biomed 2011, 10:4. 10.1186/1477-5751-10-4, 3112427, 21548990.
37. McKnight AJ, Savage DA, Patterson CC, Brady HR, Maxwell AP. Resequencing of the characterised CTGF gene to identify novel or known variants, and analysis of their association with diabetic nephropathy. J Hum Genet 2006, 51:383-386. 10.1007/s10038-006-0368-7, 16501850.
38. Wang B, Carter RE, Jaffa MA, Nakerakanti S, Lackland D, Lopes-Virella M, Trojanowska M, Luttrell LM, Jaffa AA. Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J Med Genet 2010, 47:391-397. 10.1136/jmg.2009.073098, 20522428.
39. Cozzolino M, Biondi ML, Banfi E, Riser BL, Mehmeti F, Cusi D, Gallieni M. CCN2 (CTGF) gene polymorphism is a novel prognostic risk factor for cardiovascular outcomes in hemodialysis patients. Blood Purif 2010, 30:272-276. 10.1159/000320706, 21071938.
40. Pivovarova O, Fisher E, Dudziak K, Ilkavets I, Dooley S, Slominsky P, Limborska S, Weickert MO, Spranger J, Fritsche A, Boeing H, Pfeiffer AF, Rudovich N. A polymorphism within the connective tissue growth factor (CTGF) gene has no effect on non-invasive markers of beta-cell area and risk of type 2 diabetes. Dis Markers 2011, 31:241-246.
41. Brooks BA, Franjic B, Ban CR, Swaraj K, Yue DK, Celermajer DS, Twigg SM. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 2008, 10:739-746. 10.1111/j.1463-1326.2007.00803.x, 17941867.
42. Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol 2011, 10:16. 10.1186/1475-2840-10-16, 3050685, 21303562.
43. Opstad TB, Pettersen AA, Arnesen H, Seljeflot I. Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an Observational Study. Cardiovasc Diabetol 2011, 10:110. 10.1186/1475-2840-10-110, 3295692, 22141572.
44. Cresci S, Wu J, Province MA, Spertus JA, Steffes M, McGill JB, Alderman EL, Brooks MM, Kelsey SF, Frye RL, Bach RG. Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial. Circulation 2011, 124:1426-1434. 10.1161/CIRCULATIONAHA.111.029173, 21911782.
45. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 2008, 10:35. 10.1186/1532-429X-10-35, 2467420, 18605997.